Tech Company Financing Transactions
IntraGel Therapeutics Funding Round
UroGen Pharma participated in a $7 million venture round for IntraGel Therapeutics. This VC investment round closed on 9/1/2026.
Transaction Overview
Company Name
Announced On
9/1/2026
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance its SRGel platform and accelerate the clinical development of TumoCure.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Nazareth Industrial Area Wadi, El Haj 13 P.O.Box 1252
Nazareth, 17111
Israel
Nazareth, 17111
Israel
Phone
Website
Email Address
Overview
At Intragel, we are focused on advancing next-generation long-acting injectable technologies that address some of the most persistent challenges in modern therapeutics. Our work centers on enabling safer, longer-acting injectable treatments through innovative formulation and delivery approaches. Intragel is led by a multidisciplinary team of experienced scientists and business executives with a strong track record in drug development, formulation, and commercialization. The company operates from the NGT3 technology incubator in Nazareth, Israel, and is building a platform designed to support a broad range of therapeutic applications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Siman
Browse more venture capital transactions:
Prev: 9/1/2026: Visko Platform venture capital transaction
Next: 9/1/2026: Tripo AI venture capital transaction
Share this article
News on VC Transactions
We do our best to record all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs